Posts Tagged ‘dibetes medicine’
D Medical Industries reports that its subsidiary Spring-Set Health Solutions Ltd. has successfully completed a study of usability and security of its spring report of the Universal Infusion for delivery of insulin and other drugs from a insulin pump.
The study included 48 patients in a medical center in New York. The study examined the interfaces between users, systems and operating environments, the user ends successfully in carrying out each task. D Medical has concluded: “Most users had higher scores for satisfaction and the product has been classified as safe for use by the target population.”
D Medical Hezkiah Tsoory operations manager, said: “We conducted this study in preparation, in anticipation of the Food and Drug Administration (FDA) 510 (k) for our spring games infusion universal. This major achievement was reached earlier this week. But as we make final preparations for the deployment of the United States, we are convinced that the obvious benefits of this product is going to win the hearts and minds of the American pump users. ”
Share price closed at $ 4.79 D Medical yesterday on Nasdaq, after rising 60% on Monday, giving it a market capitalization of $ 37 million. The share price fell 5.6% in the afternoon on the TASE today to NIS 16.81
Scientists have discovered a new function of insulin in the brain.
Researchers at Mount Sinai School of Medicine have found that impaired insulin action in the brain may be the result of unbridled lipolysis trigger and exacerbate type 2 diabetes in humans.
Conducted by Christoph Buettner, assistant professor of medicine, Division of Endocrinology, Diabetes and Bone Disease Mount Sinai School of Medicine, the research team first injected a small amount of insulin in the brain of rats and then assessed glucose metabolism lipids in the body. In doing so, found that brain insulin suppresses lipolysis, a process in which triglycerides are broken down into fatty acids and fatty acids are released.
Furthermore, in mice that lacked the brain insulin receptor, lipolysis was unrestrained. While fatty acids are important energy sources during fasting, they can worsen diabetes, especially when they are released after the person has eaten, as happens in people with diabetes. Researchers previously believed that insulin’s ability to suppress lipolysis was entirely mediated through insulin receptors expressed on adipocytes, or fat tissue cells.
“The major lipolysis-inducing pathway in our bodies is the sympathetic nervous system and here the studies showed that brain insulin reduces sympathetic nervous system activity in fat tissue. In patients who are obese or have diabetes, insulin fails to inhibit lipolysis and fatty acid levels are increased. The low-grade inflammation throughout the body’s tissue that is commonly present in these conditions is believed to be mainly a consequence of these increased fatty acid levels.”
Buettner added, “When brain insulin function is impaired, the release of fatty acids is increased. This induces inflammation, which can further worsen insulin resistance, the core defect in type 2 diabetes. Therefore, impaired brain insulin signaling can start a vicious cycle since inflammation can impair brain insulin signaling.
“This cycle has been preserved and can lead to type 2 diabetes. Our study raises the possibility that the increase in insulin signaling in the brain may have therapeutic benefit of the lower risk of complications of insulin therapy, which is the ‘ hypoglycemia. ”